

Benzocaine

Selected References:

- Berkovitch M, et al. 2002. Sore throat treatment during pregnancy: a prospective, controlled, pilot study. Clin Drug Invest, 22(2):135-139.
- Lezhepekova YA et al. 2024. Methemoglobinemia in a child with congenital epidermolysis bullosa. Вестник анестезиологии и реаниматологии, 21(1): 95-99.
- Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Publ Sci Group, Inc, Littleton, MA, 357-365..
- US Food and Drug Administration. 2018. Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics. <https://www.fda.gov/drugs/drug-safety-and-availability/risk-serious-and-potentially-fatal-blood-disorder-prompts-fda-action-oral-over-counter-benzocaine>.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2025.

Benzocaine

Selected References:

- Amory JK, et al. 2007. Miglustat has no apparent effect on spermatogenesis in normal men. Hum Reprod; 22(3):702-707.
- Bone W, et al. 2007. The sensitivity of murine spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic study. Reprod Biol Endocrinol; 5:1.
- Granovsky-Grisaru, S et al. 2011. The management of pregnancy in Gaucher disease. Thromb Haemost, 156:3-8.
- Hollak, C et al. 2009. Miglustat (Zavesca®) in type I Gaucher disease: 5-year results of a post-authorisation

safety surveillance programme. *Pharmacoepidemiol Drug Saf*; 18:770-777.

- Miglustat (Zavesca®) Product Label. 2021.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021348s010lbl.pdf
- Suganuma R, et al. 2005. Alkylated imino sugars, reversible male infertility-inducing agents, do not affect the genetic integrity of male mouse germ cells during short-term treatment despite induction of sperm deformities. *Biol Reprod*; 72(4):805-813.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2025.

Benzocaine

Selected References:

- Longstreth GF, et al. 2006. Functional bowel disorders. *Gastroenterology*, 130(5):1480-1491.
- Mearin F, et al. 2016. Bowel disorders. *Gastroenterology*, S0016-5085(16)00222-5.
- Shi W, et al. 2015. Epidemiology and risk factors of functional constipation in pregnant women. *PLoS One*, 10(7):e0133521.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2025.

Benzocaine

Selected References:

- Auerbach JG, Hans SL, Marcus J, Maeir S. 1992. Maternal psychotropic medication and neonatal behavior. *Neurotoxicol Teratol* 14:399-406.
- Chan J, Alldredge BK, Baskin LS. 1991. Perphenazine-induced priapism. *DICP* 24:246-9
- FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf
- FDA Drug Safety Communication. 2011. Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns: <http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm>.
- Handal M, Matheson I, Bechensteen AG, Lindemann R. 1995. [Antipsychotic agents and pregnant women. A case report]. *Tidsskr Nor Laegeforen*;115:2539-40.
- Harer WB: Tranquilizers in obstetrics and gynecology. 1958. Studies with Trilafon. *Obstet Gynecol* 11:273-9.
- Idapaan-Heikkila J, Saxen L. 1973. Possible teratogenicity of imipramine/chloropyramine. *Lancet* 2:282-4.
- Liu X, Trabjerg BB, Munk-Olsen T, Christensen J, Dreier JW. 2022. Association of Maternal Antipsychotic Prescription During Pregnancy With Standardized Test Scores of Schoolchildren in Denmark. *JAMA internal medicine*. 182(10):1035-43.
- Olesen OV, Bartels U, Poulsen JH. Perphenazine in breast milk and serum. 1990. *Am J Psychiatry*;147:1378-9.
- Reis M, Kallen B. 2008. Maternal use of antipsychotics in early pregnancy and delivery outcome. *Journal of clinical psychopharmacology*;28(3):279-88.
- Slone D et al. 1977. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. *Am J Obstet Gynecol* 128:486-8.
- Wertelecki W et al. 1980. Amitriptyline/perphenazine maternal overdose and birth defects. *Teratology* 21:74A.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2025.

Benzocaine

Selected References:

- Hallock RM, et al. 2013. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. *Drug Alcohol Depend* 130(1-3):245-8.
- Jairaj C, et al. 2022. Postpartum depression: A role for psychedelics? *Journal of Psychopharmacology* 36(8), 920-931.
- Rolsten C, 1997. Effects of chlorpromazine and psilocin on pregnancy of C57BL/10 mice and their offspring at birth. *Anat Rec* 157:311.
- Stein CA, et al. 2022. The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice. *J Midwifery Womens Health* 67(3):373-383.
- Timar L, Czeizal AE. 1997, Birth weight and congenital anomalies following poisonous mushroom intoxication during pregnancy. *Reprod Toxicol* 11: 861.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, April 1, 2025.